{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:44:19Z","timestamp":1793231059347,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uterine leiomyosarcoma (uLMS) may show loss of expression of B-cell lymphoma-2 (Bcl-2) protein. It has been suggested that Bcl-2 loss may both be a diagnostic marker and an unfavorable prognostic marker in uLMS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To define the diagnostic and prognostic value of Bcl-2 loss in uLMS through a systematic review and meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Electronic databases were searched from their inception to May 2020 for all studies assessing the diagnostic and prognostic value of Bcl-2 loss of immunohistochemical expression in uLMS. Data were extracted to calculate odds ratio (OR) for the association of Bcl-2 with uLMS <jats:italic>vs<\/jats:italic> leiomyoma variants and smooth-muscle tumors of uncertain malignant potential (STUMP), and hazard ratio (HR) for overall survival; a <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.05 was considered significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight studies with 388 patients were included. Loss of Bcl-2 expression in uLMS was not significantly associated with a diagnosis of uLMS <jats:italic>vs<\/jats:italic> leiomyoma variants and STUMP (OR\u2009=\u20092.981; <jats:italic>p<\/jats:italic>\u2009=\u20090.48). Bcl-2 loss was significantly associated with shorter overall survival in uLMS (HR\u2009=\u20093.722; <jats:italic>p<\/jats:italic>\u2009=\u20090.006). High statistical heterogeneity was observed in both analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Loss of Bcl-2 expression appears as a significant prognostic but not diagnostic marker in uLMS. The high heterogeneity observed highlights the need for further research and larger studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-022-06531-2","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T14:03:42Z","timestamp":1648476222000},"page":"379-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic and prognostic value of Bcl-2 in uterine leiomyosarcoma"],"prefix":"10.1007","volume":"307","author":[{"given":"Antonio","family":"Travaglino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-2333","authenticated-orcid":false,"given":"Antonio","family":"Raffone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Gencarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italia","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Improda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Giovanni","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Casadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Seracchioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Insabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"issue":"9252","key":"6531_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","volume":"357","author":"EA Stewart","year":"2001","unstructured":"Stewart EA (2001) Uterine fibroids. Lancet 357(9252):293\u2013298","journal-title":"Lancet"},{"issue":"4","key":"6531_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jsgi.2006.02.008","volume":"13","author":"M De Falco","year":"2006","unstructured":"De Falco M, Staibano S, D\u2019Armiento FP et al (2006) Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig 13(4):297\u2013303","journal-title":"J Soc Gynecol Investig"},{"issue":"1","key":"6531_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejogrb.2009.02.006","volume":"144","author":"M De Falco","year":"2009","unstructured":"De Falco M, Staibano S, Mascolo M et al (2009) Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol 144(1):44\u201347","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"6531_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/nbm.1540","volume":"23","author":"P Mazzei","year":"2010","unstructured":"Mazzei P, Piccolo A, Nugnes L, Mascolo M, De Rosa G, Staibano S (2010) Metabolic profile of intact tissue from uterine leiomyomas using high-resolution magic-angle-spinning 1H NMR spectroscopy. NMR Biomed 23(10):1137\u20131145","journal-title":"NMR Biomed"},{"key":"6531_CR5","volume-title":"World Health Organisation classification of tumors of female reproductive organs","author":"R Kurman","year":"2014","unstructured":"Kurman R, Carcangiu M, Herrington C, Young R (2014) World Health Organisation classification of tumors of female reproductive organs, 4th edn. International Agency for Research on Cancer (IARC) Press, Lyon","edition":"4"},{"issue":"3","key":"6531_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ygyno.2019.07.002","volume":"154","author":"A Gadducci","year":"2019","unstructured":"Gadducci A, Zannoni GF (2019) Uterine smooth-muscle tumors of unknown malignant potential: a challenging question. Gynecol Oncol 154(3):631\u2013637","journal-title":"Gynecol Oncol"},{"issue":"6","key":"6531_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/00000478-199406000-00001","volume":"18","author":"SW Bell","year":"1994","unstructured":"Bell SW, Kempson RL, Hendrickson MR (1994) Problematic uterine smooth-muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18(6):535\u201358","journal-title":"Am J Surg Pathol"},{"key":"6531_CR8","unstructured":"Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN Clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Uterine neoplasms version 1.2020 \u2013 March 06, 2020"},{"issue":"5","key":"6531_CR9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/ijms20051136","volume":"20","author":"P Rubisz","year":"2019","unstructured":"Rubisz P, Ciebiera M, Hirnle L et al (2019) The usefulness of immunohistochemistry in the differential diagnosis of lesions originating from the myometrium. Int J Mol Sci 20(5):1136","journal-title":"Int J Mol Sci"},{"issue":"12","key":"6531_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/aogs.13452","volume":"97","author":"A Travaglino","year":"2018","unstructured":"Travaglino A, Raffone A, Saccone G et al (2018) Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 97(12):1415\u20131426","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"10","key":"6531_CR11","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6690578","volume":"80","author":"YL Zhai","year":"1999","unstructured":"Zhai YL, Nikaido T, Toki T, Shiozawa A, Orii A, Fujii S (1999) Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 80(10):1658\u20131664","journal-title":"Br J Cancer"},{"issue":"1","key":"6531_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ygyno.2005.09.055","volume":"101","author":"AL Leiser","year":"2006","unstructured":"Leiser AL, Anderson SE, Nonaka D et al (2006) Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol 101(1):86\u201391","journal-title":"Gynecol Oncol"},{"issue":"7","key":"6531_CR13","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1245\/s10434-012-2834-0","volume":"20","author":"K Lusby","year":"2013","unstructured":"Lusby K, Savannah KB, Demicco EG et al (2013) Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution\u2019s experience. Ann Surg Oncol 20(7):2364\u20132372","journal-title":"Ann Surg Oncol"},{"key":"6531_CR14","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.2147\/OTT.S142979","volume":"10","author":"T Banas","year":"2017","unstructured":"Banas T, Pitynski K, Okon K, Czerw A (2017) DNA fragmentation factors 40 and 45 (DFF40\/DFF45) and B-cell lymphoma 2 (Bcl-2) protein are underexpressed in uterine leiomyosarcomas and may predict survival. Onco Targets Ther 10:4579\u20134589","journal-title":"Onco Targets Ther"},{"issue":"2","key":"6531_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ygyno.2011.01.022","volume":"121","author":"E D'Angelo","year":"2011","unstructured":"D\u2019Angelo E, Espinosa I, Ali R et al (2011) Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 121(2):328\u2013333","journal-title":"Gynecol Oncol"},{"issue":"2","key":"6531_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","volume":"155","author":"A Raffone","year":"2019","unstructured":"Raffone A, Travaglino A, Mascolo M et al (2019) TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol 155(2):374\u2013383","journal-title":"Gynecol Oncol"},{"issue":"11","key":"6531_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/apm.12988","volume":"127","author":"A Travaglino","year":"2019","unstructured":"Travaglino A, Raffone A, Saccone G et al (2019) Nuclear expression of \u03b2-catenin in endometrial hyperplasia as marker of premalignancy. APMIS 127(11):699\u2013709","journal-title":"APMIS"},{"key":"6531_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1","journal-title":"Syst Rev"},{"issue":"8","key":"6531_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529\u2013536","journal-title":"Ann Intern Med"},{"issue":"2","key":"6531_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/his.13976","volume":"76","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Mascolo M et al (2020) Clear cell endometrial carcinoma and the TCGA classification. Histopathology 76(2):336\u2013338","journal-title":"Histopathology"},{"issue":"1","key":"6531_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/ajcp\/aqz132","volume":"153","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Saccone G et al (2020) Congruence between 1994 WHO classification of endometrial hyperplasia and endometrial intraepithelial neoplasia system. Am J Clin Pathol 153(1):40\u201348","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"6531_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00404-019-05299-2","volume":"300","author":"A Travaglino","year":"2019","unstructured":"Travaglino A, Raffone A, Saccone G et al (2019) Significant risk of occult cancer in complex non-atypical endometrial hyperplasia. Arch Gynecol Obstet 300(5):1147\u20131154","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"6531_CR23","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s12253-019-00784-0","volume":"26","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Mascolo M et al (2020) TCGA molecular subgroups in endometrial undifferentiated\/dedifferentiated carcinoma. Pathol Oncol Res 26(3):1411\u20131416","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"6531_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jsgi.2003.10.003","volume":"11","author":"K Bodner","year":"2004","unstructured":"Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K (2004) Bcl-2 receptor expression in patients with uterine smooth-muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth-muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig 11(3):187\u2013191","journal-title":"J Soc Gynecol Investig"},{"issue":"1","key":"6531_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1582-4934.2006.tb00300.x","volume":"10","author":"L Rath-Wolfson","year":"2006","unstructured":"Rath-Wolfson L, Rosenblat Y, Halpern M et al (2006) A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth-muscle tumors. J Cell Mol Med 10(1):197\u2013205","journal-title":"J Cell Mol Med"},{"issue":"3 Suppl","key":"6531_CR26","first-page":"1129","volume":"55","author":"AD St\u0103nescu","year":"2014","unstructured":"St\u0103nescu AD, Nistor E, Sajin M, Stepan AE (2014) Immunohistochemical analysis in the diagnosis of uterine myometrial smooth-muscle tumors. Rom J Morphol Embryol 55(3 Suppl):1129\u20131136","journal-title":"Rom J Morphol Embryol"},{"issue":"1","key":"6531_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408360500295626","volume":"43","author":"H Thomadaki","year":"2006","unstructured":"Thomadaki H, Scorilas A (2006) BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 43(1):1\u201367","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"6531_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/gut.43.3.383","volume":"43","author":"M Ilyas","year":"1998","unstructured":"Ilyas M, Hao XP, Wilkinson K et al (1998) Loss of Bcl-2 expression correlates with tumor recurrence in colorectal cancer. Gut 43(3):383\u2013387","journal-title":"Gut"},{"key":"6531_CR29","first-page":"293","volume":"82","author":"H Matsuo","year":"1997","unstructured":"Matsuo H, Maruo T, Samoto T (1997) Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82:293\u2013299","journal-title":"J Clin Endocrinol Metab"},{"key":"6531_CR30","first-page":"487","volume":"44","author":"KK Khurana","year":"1999","unstructured":"Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ (1999) Maintenance of increased Bcl-2 expression in uterine leiomyomas after gnrh agonist therapy. J Reprod Med 44:487\u2013492","journal-title":"J Reprod Med"},{"issue":"1","key":"6531_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/or.2016.5274","volume":"37","author":"D Conconi","year":"2017","unstructured":"Conconi D, Chiappa V, Perego P et al (2017) Potential role of BCL2 in the recurrence of uterine smooth-muscle tumors of uncertain malignant potential. Oncol Rep 37(1):41\u201347","journal-title":"Oncol Rep"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06531-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06531-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06531-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T15:06:18Z","timestamp":1680707178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06531-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["6531"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06531-2","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"8 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}